FDA on Pace to Approve More New Drugs in 2012 Than the 30 Approved in 2011

Five Star Equities Provides Stock Research on CytRx and ZIOPHARM Oncology

Continue Reading

Guidelines of New “Stress Tests” Announced – Focused on the Handling of Major Recessions in China and Europe

Five Star Equities Provides Stock Research on U.S. Bancorp and Hudson City Bancorp

Continue Reading

U.S. Forecasted by the IEA to Be the World-s Top Oil Producer by 2020

The Paragon Report Provides Stock Research on Goodrich Petroleum and Talisman Energy

Continue Reading

Biotech Industry Experiencing a Higher Amount of FDA New Drug Approvals in 2012

Five Star Equities Provides Stock Research on Discovery Laboratories and Cardium Therapeutics

Continue Reading

Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry-s Success in 2012

Five Star Equities Provides Stock Research on Ariad Pharmaceuticals and AVEO Pharmaceuticals

Continue Reading

Gold Futures Surge to 1 Month Highs on Optimism That the Upcoming “Fiscal Cliff” Can Be Avoided

The Paragon Report Provides Stock Research on Newmont Mining and Goldcorp

Continue Reading

Gold Futures Reach 1-Month High as Lawmakers Seek to Find Solution for Upcoming “Fiscal Cliff”

The Paragon Report Provides Stock Research on Kinross Gold and Yamana Gold

Continue Reading

Improving Trend in FDA First Cycle Review Approvals a Major Factor for Biotech Industry-s Success in 2012

Five Star Equities Provides Stock Research on Amgen and Regeneron Pharmaceuticals

Continue Reading

Analysts Predict Bullish Short-Term Outlook for Gold as Lawmakers Look to Avoid “Fiscal Cliff”

The Paragon Report Provides Stock Research on Eldorado Gold and New Gold

Continue Reading

Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases

Five Star Equities Provides Stock Research on Orexigen Therapeutics and PDL BioPharma

Continue Reading